Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prospective paired study of L3 skeletal muscle index changes during active nutrition and exercise intervention in albumin-paclitaxel chemotherapy
ChiCTR2500095637Phase 4Not yet recruiting
- Sponsor
- Ordos Central Hospital
- Start
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of paclitaxel in cancer (2 arms), sponsored by Ordos Central Hospital. Primary endpoint: Index of the third lumbar vertebra corresponding to skeletal muscle (L3 skeletal muscle index, L3 SMI). Planned start Jan 2025; status: not yet recruiting.
02
Drugs
paclitaxel
03
Conditions
cancer
Beyond the preview
Go deeper on ChiCTR2500095637.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500095637.